Posts in category Most Popular

vTv Therapeutics (VTVT) Stock: Healthcare Analysts Move to the Sidelines

Last week, vTv Therapeutics Inc (NASDAQ:VTVT) announced that azeliragon, the company’s RAGE inhibitor in development …

Tesla (TSLA) Still a ‘Show Me’ Story (In a Bad Way), Twitter (TWTR) Stock Wins an Upgrade

What does the future hold for Tesla (NASDAQ:TSLA) and Twitter (NYSE:TWTR)? Sell-side analysts from Bernstein and Morgan …

Bristol Myers Squibb (BMY) Will Face Significant Headwinds in 2019; Here’s Why

Yesterday, Merck (NYSE:MRK) reported data from Keytruda in combo with chemotherapy for patients with non-small …

Will Crypto Risk Hang Over Advanced Micro Devices (AMD) Shares? Wells Fargo Weighs In

David Wong is upbeat on AMD’s sharpening competitive edge in microprocessor to graphics markets.

Sphere 3D (ANY) Shares Stumble Out of the Gate; What Investors Need to Know

Shares of virtualization and data management company Sphere 3D (NASDAQ:ANY) are collapsing – down nearly …

Spectrum Pharmaceuticals’ (SPPI) Encouraging Clinical Update in NSCLC Gets the Bulls in a Buying Frenzy

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) just riled up Wall Street today with enticing Phase 2 study …

ACADIA Pharmaceuticals (ACAD): Top Analyst Does Not See ‘Real Safety Signal’ for Nuplazid

Cowen’s Ritu Baral’s conversations with key experts in the field with Nuplazid experience leave her positive; albeit somewhat ‘cautious’ on the impact of ACAD’s controversy.

Should You Worry About NVIDIA (NVDA) Stock Weakness? Top Analyst Says No

Needham’s Rajvindra Gill sees not much of a financial impact to NVDA shares on the heels of a troublesome round of negative headlines.

Protagonist Therapeutics’ (PTGX) Bulls Are Running For The Hills, But Upside Remains

Though Tim Chiang meaningfully scales back his target expectations, he still sees 60% potential upside for PTGX shares thanks to its tech platform.

Nutanix Inc (NTNX) Wins Another Price Target Boost

Yet another analyst has weighed in on Nutanix Inc (NASDAQ:NTNX) and pushed sales forecast higher for the hyper-converged …